Efficacy and Safety of a Therapy Change From Candesartan 32 mg to Fixed Combination of Olmesartan 40 mg/Amlodipine 10 mg (Sevicontrol-2)
Efficacy and Safety of a Sequential Therapy Change From Candesartan 32 mg to the Fixed Combination of Olmesartan 40 mg/Amlodipine 10 mg in Patients With Poorly Controlled Moderate Hypertension - an Open Phase IV Trial
Sponsor: Institut für Pharmakologie und Präventive Medizin
Listed as NCT01611077, this PHASE4 trial focuses on Hypertension and remains completed. Sponsored by Institut für Pharmakologie und Präventive Medizin, it has been updated 6 times since 2012, reflecting limited change activity. This study contributes longitudinal data to the cardiovascular research landscape.
Status Flow
Change History
6 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE4
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE4
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE4
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE4
▶ Show 1 earlier version
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE4
First recorded
Jan 2012
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Institut für Pharmakologie und Präventive Medizin
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Anderbeck, Germany , Bergisch Gladbach, Germany , Berlin, Germany , Cloppenburg, Germany , Dresden, Germany , Essen, Germany , Frankfurt, Germany , Kapellendorf, Germany , Leipzig, Germany , Ludwigshafen, Germany and 1 more location